Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 13/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372953 | 0.77 | SRD5A1 (0.54) | CYP11B2CYP19A1CYP11B1SRD5A1PARP1 | |
| SCHEMBL13849161 | 0.77 | CYP11B2 (0.46) | CYP11B2CYP19A1CYP11B1SRD5A1PARP1 | |
| SCHEMBL4574918 | 0.76 | CYP11B2 (0.45) | CYP11B2CYP19A1CYP11B1SRD5A1PARP1 | |
| SCHEMBL192610 | 0.76 | CASP1 (0.59) | CYP11B2CYP19A1CYP11B1SRD5A1 | |
| SCHEMBL29726050 | 0.76 | CASP1 (0.59) | CYP11B2CYP19A1CYP11B1SRD5A1 | |
| SCHEMBL8252930 | 0.76 | CYP11B2 (0.45) | CYP11B2CYP19A1CYP11B1SRD5A1PARP1 | |
| SCHEMBL7665011 | 0.74 | PARP10 (0.46) | CYP11B2CYP19A1CYP11B1SRD5A1PARP10 | |
| SCHEMBL3369697 | 0.73 | HTT (0.55) | CYP11B2CYP19A1CYP11B1SRD5A1PARP1 | |
| SCHEMBL15395903 | 0.72 | CYP11B2 (0.42) | CYP11B2CYP19A1CYP11B1SRD5A1PARP1 | |
| SCHEMBL4045716 | 0.72 | CYP11B2 (0.46) | CYP11B2CYP19A1CYP11B1SRD5A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716132-B1 | SPIRO-BENZODIOXOLES AND THEIR USE AS CB1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-7144890-B2 | Spiro-pentacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050165012-A1 | Spiro-pentacyclic compounds | HOFFMANN-LA ROCHE INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165012-A1 | Spiro-pentacyclic compounds | CNR1, CNR2, GPR119 | CYP11B2 134/4885CYP19A1 212/4885CYP11B1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.